Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes

Biochemical and Biophysical Research Communications

Volumn 344, Issue 3, 2006, Pages 1017-1022

  Yang, Zandong ^a   Chen, Meng ^a   Carter, Jeffrey D ^a   Nunemaker, Craig S ^a   Garmey, James C ^a   Kimble, Sarah D ^a   Nadler, Jerry L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Cell neogenesis; Autoimmunity; Cytokine; Exendin 4; Inflammation; Islet; Lisofylline; Non obese diabetic (NOD) mice; Proliferation; Type 1 diabetes

Indexed keywords

EXENDIN 4; HUMAN INSULIN; LISOFYLLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; IMMUNOCYTOCHEMISTRY; INSULIN RELEASE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; TREATMENT WITHDRAWAL;

ANIMALS; DIABETES MELLITUS, TYPE 1; DRUG COMBINATIONS; INSULIN-SECRETING CELLS; MICE; MICE, INBRED C57BL; PENTOXIFYLLINE; PEPTIDES; TREATMENT OUTCOME; VENOMS;

ANIMALIA;

EID: 33646163679     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.03.177     Document Type: Article

References (25)

1. Orskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35 8 (1992) 701-711
2. Drucker D.J. Minireview: the glucagon-like peptides. Endocrinology 142 (2001) 521-527
3. Nauck M.A., Bartels E., Orskov C., Ebert R., and Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol. Metab. 76 (1993) 912-917
4. Zhou J., Wang X., Pineyro M.A., and Egan J.M. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 48 (1999) 2358-2366
5. Parkes D.G., Pittner R., Jodka C., Smith P., and Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 50 (2001) 583-589
6. Xu G., Stoffers D.A., Habener J.F., and Bonner-Weir S. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 (1999) 2270-2276
7. Zhou J., Pineyro M.A., Wang X., Doyle M.E., and Egan J.M. Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3β transcription factors. J. Cell. Physiol. 192 (2002) 304-314
8. Ogawa N., List J.F., Habener J.F., and Maki T. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 53 (2004) 1700-1705
9. Yang Z., Chen M., Wu R., McDuffie M., and Nadler J.L. The anti-inflammatory compound lisofylline prevents type I diabetes in non-obese diabetic mice. Diabetologia 45 (2002) 1307-1314
10. Yang Z., Chen M., Fialkow L.B., Ellett J.D., Wu R., and Nadler J.L. The novel anti-inflammatory compound, lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice. Pancreas 26 (2003) e99-e104
11. Rice G.C., Rosen J., Weeks R., Michnick J., Bursten S., Bianco J.A., and Singer J.W. CT-1501R selectively inhibits induced inflammatory monokines in human whole blood ex vivo. Shock 1 (1994) 254-266
12. Coon M.E., Diegel M., Leshinsky N., and Klaus S.J. Selective pharmacologic inhibition of murine and human IL-12-dependent Th1 differentiation and IL-12 signaling. J. Immunol. 163 (1999) 6567-6574
13. Bright J.J., Du C., Coon M., Sriram S., and Klaus S.J. Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: an effect of the novel anti-inflammatory drug lisofylline. J. Immunol. 161 (1998) 7015-7022
14. Yang Z., Chen M., Fialkow L.B., Ellett J.D., Wu R., and Nadler J.L. Inhibition of STAT4 activation by lisofylline is associated with the protection of autoimmune diabetes. Ann. N.Y. Acad. Sci. 1005 (2003) 409-411
15. Yang Z., Chen M., Ellett J.D., Fialkow L.B., Carter J.D., McDuffie M., and Nadler J.L. Autoimmune diabetes is blocked in Stat4-deficient mice. J. Autoimmun. 22 (2004) 191-200
16. Yang Z., Chen M., and Nadler J.L. Lisofylline: a potential lead for the treatment of diabetes. Biochem. Pharmacol. 69 (2005) 1-5
17. Yang Z., Chen M., Ellett J.D., Fialkow L.B., Carter J.D., and Nadler J.L. The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrence after islet transplantation. Transplantation 77 (2004) 55-60
18. Yang Z., Chen M., Carter J.D., Ellett J.D., Smith K.M., and Nadler J.L. Inflammation blockade improves pancreatic islet function. Transplant. Proc. 36 (2004) 2864-2865
19. Yang Z., Chen M., Ellett J.D., Carter J.D., Brayman K.L., and Nadler J.L. Inflammatory blockade improves human pancreatic islet function and viability. Am. J. Transplant. (2005) 475-483
20. Chen M., Yang Z., Wu R., and Nadler J.L. Lisofylline, a novel antiinflammatory agent, protects pancreatic β-cells from proinflammatory cytokine damage by promoting mitochondrial metabolism. Endocrinology 143 (2002) 2341-2348
21. Bleich D., Chen S., Bursten S.L., and Nadler J.L. Lisofylline, an inhibitor of unsaturated phosphatidic acid generation, ameliorates interleukin-1 β-induced dysfunction in cultured rat islets. Endocrinology 137 (1996) 4871-4877
22. Makino S., Kunimoto K., Muraoka Y., Mizushima Y., Katagiri K., and Tochino Y. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 29 (1980) 1-13
23. Bonner-Weir S., and Weir G.C. New sources of pancreatic β-cells. Nat. Biotechnol. 23 (2005) 857-861
24. Trucco M. Regeneration of the pancreatic β cell. J. Clin. Invest. 115 (2005) 5-12
25. Meier J.J., Bhushan A., Butler A.E., Rizza R.A., and Butler P.C. Sustained β cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration?. Diabetologia 48 (2005) 2221-2228